A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported first-quarter earnings
Spinraza helps Biogen beat the street in Q1
![Earnings Update by AlphaStreet](https://cdn.news.alphastreet.com/wp-content/uploads/2019/04/Earnings-Coverage-4.jpg)
A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported first-quarter earnings
Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the
Amarin Corporation (NASDAQ: AMRN) shares got a major boost during the pre-market hours of Thursday after it said the American Diabetes Association
Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular trading hours.
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped
Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in fiscal 2018
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is
NVAX Earnings Transcripts NVAX Earnings Calendar Clinical-stage vaccine company Novavax (NVAX) reported a loss of 13 per share in the fourth
Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market trading. Helped
Shares of Portola Pharmaceuticals (PTLA) gained 5.6% during pre-market trading on Friday, after the company posted a loss of $1.04 per share,
Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an acquisition once
CVS Health Corporation (CVS) is scheduled to report fourth-quarter earnings results before the regular trading hours on Wednesday, February 20. The retail
AstraZeneca Plc (AZN) reported a 22% dip in earnings for the fourth quarter to 82 cents per share, weighed down higher costs.
Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a
Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million
Pfizer (PFE) reported a better-than-expected 2% increase in fourth-quarter revenues to $13.9 billion. Earnings rose to 64 cents per share from 62
Only two weeks after announcing its massive acquisition of Celgene Corporation, drug-maker Bristol-Myers Squibb (BMY) is all set to report fourth-quarter results
Shares of Ligand Pharmaceuticals (LGND) took a beating on Wednesday after a bearish report by Citron Research led by short-seller Andrew Left
Eli Lilly and Company (LLY) on Monday announced that it would acquire a small biopharmaceutical startup that develops cancer treatment, Loxo Oncology
Johnson & Johnson (JNJ) shares fell 1% on Thursday after the company reported a 3% sales dip in India in the year
The tainted talc has been snowballing into a gigantic threat since 2016, and things are not looking good as Johnson & Johnson